Diacerein for COVID-19: real-time analysis

Download Image

Post

c19early.org

Diacerein for COVID-19

1 study with 14 patients

Serious outcome risk

Diacerein

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Diacerein studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−10%

Hospitalization (1)−10%

RCTs (1)−10%

Late (1)−10%

00.511.5+

← Diacerein
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Diacerein is an oral, small molecule anti-inflammatory drug that inhibits the interleukin-1β (IL-1β) pathway and inflammasome activation.


Oct 7 2024	Carmo et al., Frontiers in Pharmacology, doi:10.3389/fphar.2024.1402032	Diacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study
Oct 7 2024	10% longer hospitalization (p=0.79). RCT 14 hospitalized patients with mild to moderate COVID-19 showing reduced plasma inflammasome markers with diacerein treatment, but no significant difference in duration of hospitalization. The study was halted early due to declining CO..